Forte Biosciences, Inc. (FBRX) |
| 17 1.33 (8.49%) 06-09 16:00 |
| Open: | 15.79 |
| High: | 17.07 |
| Low: | 15.53 |
| Volume: | 414,923 |
| Market Cap: | 236(M) |
| PE Ratio: | -3.71 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 29.15 |
| Resistance 1: | 23.94 |
| Pivot price: | 19.17 |
| Support 1: | 15.51 |
| Support 2: | 12.90 |
| 52w High: | 35.8 |
| 52w Low: | 9.1 |
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Financials
| EPS | -4.580 |
| Book Value | 3.030 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -83.9 |
| Return on Equity (ttm) | -188.4 |
Company news
Mon, 08 Jun 2026
Millennium Group (FBRX) reports shared control of 1,062,182 shares - Stock Titan
Fri, 05 Jun 2026
FORTE BIOSCIENCES INC (FBRX) Stock Chart - ChartMill
Fri, 05 Jun 2026
Forte Biosciences (NASDAQ: FBRX) files $500M shelf to sell securities - Stock Titan
Fri, 05 Jun 2026
FBRX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Tue, 02 Jun 2026
Forte Biosciences (NASDAQ: FBRX) director receives 18,353 RSU equity award - Stock Titan
Tue, 02 Jun 2026
Forte Biosciences (FBRX) director awarded 18,353 restricted stock units in equity grant - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
